A life-threatening drug-drug interaction between capecitabine and brivudine in a patient with metastatic breast cancer.
Capecitabine
breast cancer
brivudine
dihydropyrimidine dehydrogenase
drug interactions
mucositis
pancytopenia
Journal
Journal of chemotherapy (Florence, Italy)
ISSN: 1973-9478
Titre abrégé: J Chemother
Pays: England
ID NLM: 8907348
Informations de publication
Date de publication:
Historique:
pubmed:
14
9
2019
medline:
30
4
2020
entrez:
14
9
2019
Statut:
ppublish
Résumé
In the current report we present the case of a patient experiencing a life-threatening drug-drug interaction involving the concurrent administration of capecitabine and brivudine. A 65- year-old female with metastatic breast cancer was commenced on brivudine for Herpes Zoster, while on capecitabine treatment, by a physician unfamiliar with the potential repercussions of this drug-drug interaction. As a result, she developed skin rash, severe oral mucositis, and severe and prolonged pancytopenia. These side effects were attributed to a serious interaction of capecitabine with brivudine, resulting in inhibition of dihydropyrimidine dehydrogenase. The patient was admitted for supportive care including intravenous hydration, parenteral nutrition, mouth care solutions, fluconazole, antimicrobial therapy, filgrastim, red blood cell and platelet transfusions. She successfully recovered and was discharged on the 26
Identifiants
pubmed: 31516092
doi: 10.1080/1120009X.2019.1665875
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Antiviral Agents
0
brivudine
2M3055079H
Capecitabine
6804DJ8Z9U
Bromodeoxyuridine
G34N38R2N1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM